Table 2.

Prospective clinical trials evaluating immune checkpoint inhibitors in advanced non-small cell lung cancer patients which included patients with ALK-rearranged non-small cell lung cancer.

Trial	Author/Year	Total No. of Patients	Treatment	No. of Patients with ALK Rearrangements in Immunotherapy Arm vs. Chemotherapy Arm (%)	Median OS (in the Entire Study Population) *
CheckMate 057	Borghei 2015 [32]	582	Nivolumab vs. docetaxel	13 (4%) vs. 8 (3%)	12.2 vs. 9.4 m.
Keynote-010	Herbst 2016 [33]	1034	Pembrolizumab vs. docetaxel	7 (1%) vs. 2 (0.5%)	10.4 vs. 12.7 m.
POPLAR	Fehrenbacher 2016 [34]	287	Atezolizumab vs. docetaxel	0 vs. 3 (2%)	12.6 vs. 9.7 m.
OAK	Rittmeyer 2017 [34]	1225	Atezolizumab vs. docetaxel	2 (<1%) vs. 0	13.8 vs. 9.6 m.

* Median OS in the ALK rearranged population was not reported due to too few patients.